Compare LULU & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LULU | DGX |
|---|---|---|
| Founded | 1998 | 1967 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.9B | 20.5B |
| IPO Year | 2007 | 1996 |
| Metric | LULU | DGX |
|---|---|---|
| Price | $190.87 | $182.89 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 28 | 15 |
| Target Price | ★ $228.77 | $194.07 |
| AVG Volume (30 Days) | ★ 3.1M | 1.2M |
| Earning Date | 12-11-2025 | 10-21-2025 |
| Dividend Yield | N/A | ★ 1.75% |
| EPS Growth | 13.74 | ★ 14.49 |
| EPS | ★ 14.72 | 8.51 |
| Revenue | ★ $10,904,036,000.00 | $10,850,000,000.00 |
| Revenue This Year | $5.67 | $12.37 |
| Revenue Next Year | $4.41 | $3.52 |
| P/E Ratio | ★ $12.91 | $21.44 |
| Revenue Growth | 9.16 | ★ 13.74 |
| 52 Week Low | $159.25 | $148.70 |
| 52 Week High | $423.32 | $197.55 |
| Indicator | LULU | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 68.55 | 44.87 |
| Support Level | $178.90 | $184.18 |
| Resistance Level | $185.07 | $185.12 |
| Average True Range (ATR) | 5.56 | 3.22 |
| MACD | 2.01 | -0.78 |
| Stochastic Oscillator | 94.04 | 3.85 |
Lululemon Athletica designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. The company offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. Lululemon also sells fitness accessories, such as bags, yoga mats, and equipment. It sells its products through digital channels, a small number of wholesale partners, more than 780 company-owned stores in about two dozen countries in North America, Asia, and Western Europe, and about 40 franchised locations in the Middle East and Europe. The company was founded in 1998 and is based in Vancouver, Canada.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.